Eighteen years ago, the EORTC PET criteria standardized for the first time response
assessment by FDG PET. Response assessment by FDG PET has been further developed …

OBJECTIVE. FDG PET/CT affects the management of patients with breast cancer in multiple
settings, including initial staging, treatment response assessment, and evaluation of …

Background The current study was conducted to evaluate the efficacy and safety of
pembrolizumab‐mediated programmed cell death protein 1 inhibition plus radiotherapy (RT) …

Breast cancer prognosis is steadily improving due to early detection of primary cancer in
screening programs and revolutionizing treatment development. In the metastatic setting …

Breast cancer is the most common cancer among women in the United States and the
second leading cause of cancer-related deaths; approximately 12.9% of women will be …

Purpose To provide an organized, international, state-of-the-art, and multidisciplinary
guideline, led by experts of two nuclear medicine societies (EANM and SNMMI) and …

Simple Summary In patients with advanced radioiodine refractory differentiated thyroid
carcinoma (DTC), therapeutic options are limited. In the “Study of (E7080) Lenvatinib in …

The role of fludeoxyglucose (FDG) PET in the management of patients with breast cancer
(BC) is evolving. Combined PET and computed tomography (CT) systems (PET/CT) have …

Background: We aimed to examine the feasibility and potential benefit of applying PET
Response Criteria in Solid Tumors (PERCIST) for response monitoring in metastatic breast …

Abstract Positron Emission tomography Response Criteria In Solid Tumors (PERCIST)
version 1.0 was introduced in 2009 for objective assessment of tumor metabolic response …